Analyzing IceCure Medical (NASDAQ:ICCM) and Zicix (OTCMKTS:ZICXD)

IceCure Medical (NASDAQ:ICCM) and Zicix (OTCMKTS:ZICXD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Profitability

This table compares IceCure Medical and Zicix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
Zicix	N/A	N/A	N/A

Risk & Volatility

IceCure Medical has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Zicix has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Valuation & Earnings

This table compares IceCure Medical and Zicix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	2.34	-$15.06 million	($7.21)	-0.39
Zicix	N/A	N/A	N/A	($100.14)	-0.01

Zicix has lower revenue, but higher earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Zicix, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.6% of IceCure Medical shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for IceCure Medical and Zicix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1	1	3	0	2.40
Zicix	0	0	0	0	0.00

IceCure Medical currently has a consensus target price of $62.70, suggesting a potential upside of 2,131.32%. Given IceCure Medical’s stronger consensus rating and higher possible upside, equities analysts plainly believe IceCure Medical is more favorable than Zicix.

Summary

IceCure Medical beats Zicix on 7 of the 12 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.